TipRanks
Celldex Therapeutics Inc (CH:TCE1)
:TCE1
Switzerland Market
TCE1
Celldex
RESEARCH TOOLSreports

Celldex (TCE1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

TCE1 Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Celldex
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TCE1 Stock 12 Month Forecast

Average Price Target

―
Based on 12 Wall Street analysts offering 12 month price targets for Celldex in the last 3 months. The average price target is CHF55.06 with a high forecast of CHF83.22 and a low forecast of CHF23.30. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF83.22Average Price TargetCHF55.06Lowest Price TargetCHF23.30
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on CH:TCE1
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF50.76→CHF59.92
Buy
―
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Summit Therapeutics (NASDAQ: SMMT) and AbbVie (NYSE: ABBV)
H.C. Wainwright Analyst forecast on CH:TCE1
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF53.26
Buy
―
Reiterated
10/05/26
Celldex adverse event concerns overblown, says H.C. WainwrightCelldex adverse event concerns overblown, says H.C. Wainwright
Goldman Sachs Analyst forecast on CH:TCE1
Richard Law CFA
Goldman Sachs
Goldman Sachs
CHF31.62→CHF23.3
Hold
―
Reiterated
10/05/26
Goldman Sachs Keeps Their Hold Rating on Celldex (CLDX)
LifeSci Capital Analyst forecast on CH:TCE1
Sam Slutsky
LifeSci Capital
LifeSci Capital
CHF46.6→CHF53.26
Buy
―
Reiterated
10/03/26
Celldex (CLDX) Receives a Rating Update from a Top Analyst
Leerink Partners Analyst forecast on CH:TCE1
Thomas Smith
Leerink Partners
Leerink Partners
CHF58.25→CHF73.23
Buy
―
Reiterated
09/23/26
Celldex price target raised to $88 from $70 at LeerinkCelldex price target raised to $88 from $70 at Leerink
Canaccord Genuity Analyst forecast on CH:TCE1
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF49.93
Buy
―
Reiterated
09/23/26
Canaccord Genuity Sticks to Their Buy Rating for Celldex (CLDX)
Wells Fargo Analyst forecast on CH:TCE1
Derek Archila
Wells Fargo
Wells Fargo
CHF59.92
Buy
―
Reiterated
09/23/26
Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)
Morgan Stanley Analyst forecast on CH:TCE1
Judah Frommer
Morgan Stanley
Morgan Stanley
CHF47.43
Buy
―
Assigned
09/23/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Celldex (NASDAQ: CLDX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Barclays Analyst forecast on CH:TCE1
Etzer Darout
Barclays
Barclays
CHF44.1
Buy
―
Reiterated
09/22/26
Barclays Sticks to Their Buy Rating for Celldex (CLDX)
Stifel Nicolaus Analyst forecast on CH:TCE1
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
CHF48.26→CHF56.59
Buy
―
Assigned
09/22/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Celldex (NASDAQ: CLDX) and Inventiva (NASDAQ: IVA)
Guggenheim Analyst forecast on CH:TCE1
Yatin Suneja
Guggenheim
Guggenheim
CHF83.22
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Adicet Bio (NASDAQ: ACET) and Amgen (NASDAQ: AMGN)
Jefferies Analyst forecast on CH:TCE1
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF56.59
Buy
―
Reiterated
08/07/26
Celldex (CLDX) Gets a Buy from Jefferies
UBS Analyst forecast on CH:TCE1
David Dai
UBS
UBS
CHF37.45
Buy
―
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Wolfe Research Analyst forecast on CH:TCE1
Andy Chen
Wolfe Research
Wolfe Research
CHF42.44→CHF36.61
Buy
―
Reiterated
06/14/26
Celldex (CLDX) Receives a Buy from Wolfe Research
TD Cowen Analyst forecast on CH:TCE1
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on CH:TCE1
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF50.76→CHF59.92
Buy
―
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Summit Therapeutics (NASDAQ: SMMT) and AbbVie (NYSE: ABBV)
H.C. Wainwright Analyst forecast on CH:TCE1
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
CHF53.26
Buy
―
Reiterated
10/05/26
Celldex adverse event concerns overblown, says H.C. WainwrightCelldex adverse event concerns overblown, says H.C. Wainwright
Goldman Sachs Analyst forecast on CH:TCE1
Richard Law CFA
Goldman Sachs
Goldman Sachs
CHF31.62→CHF23.3
Hold
―
Reiterated
10/05/26
Goldman Sachs Keeps Their Hold Rating on Celldex (CLDX)
LifeSci Capital Analyst forecast on CH:TCE1
Sam Slutsky
LifeSci Capital
LifeSci Capital
CHF46.6→CHF53.26
Buy
―
Reiterated
10/03/26
Celldex (CLDX) Receives a Rating Update from a Top Analyst
Leerink Partners Analyst forecast on CH:TCE1
Thomas Smith
Leerink Partners
Leerink Partners
CHF58.25→CHF73.23
Buy
―
Reiterated
09/23/26
Celldex price target raised to $88 from $70 at LeerinkCelldex price target raised to $88 from $70 at Leerink
Canaccord Genuity Analyst forecast on CH:TCE1
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF49.93
Buy
―
Reiterated
09/23/26
Canaccord Genuity Sticks to Their Buy Rating for Celldex (CLDX)
Wells Fargo Analyst forecast on CH:TCE1
Derek Archila
Wells Fargo
Wells Fargo
CHF59.92
Buy
―
Reiterated
09/23/26
Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)
Morgan Stanley Analyst forecast on CH:TCE1
Judah Frommer
Morgan Stanley
Morgan Stanley
CHF47.43
Buy
―
Assigned
09/23/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE), Celldex (NASDAQ: CLDX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Barclays Analyst forecast on CH:TCE1
Etzer Darout
Barclays
Barclays
CHF44.1
Buy
―
Reiterated
09/22/26
Barclays Sticks to Their Buy Rating for Celldex (CLDX)
Stifel Nicolaus Analyst forecast on CH:TCE1
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
CHF48.26→CHF56.59
Buy
―
Assigned
09/22/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Celldex (NASDAQ: CLDX) and Inventiva (NASDAQ: IVA)
Guggenheim Analyst forecast on CH:TCE1
Yatin Suneja
Guggenheim
Guggenheim
CHF83.22
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Adicet Bio (NASDAQ: ACET) and Amgen (NASDAQ: AMGN)
Jefferies Analyst forecast on CH:TCE1
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF56.59
Buy
―
Reiterated
08/07/26
Celldex (CLDX) Gets a Buy from Jefferies
UBS Analyst forecast on CH:TCE1
David Dai
UBS
UBS
CHF37.45
Buy
―
Reiterated
06/16/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Wolfe Research Analyst forecast on CH:TCE1
Andy Chen
Wolfe Research
Wolfe Research
CHF42.44→CHF36.61
Buy
―
Reiterated
06/14/26
Celldex (CLDX) Receives a Buy from Wolfe Research
TD Cowen Analyst forecast on CH:TCE1
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
REPLReplimune Group
OVIDOvid Therapeutics
IMUXImmunic
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Celldex

3 Months
Joseph PantginisH.C. Wainwright
Success Rate
10/16 ratings generated profit
63%
Average Return
+3.00%
Copying Joseph Pantginis's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +3.00% per trade.
1 Year
Kristen KluskaCantor Fitzgerald
Success Rate
14/24 ratings generated profit
58%
Average Return
+65.93%
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +65.93% per trade.
2 Years
Derek ArchilaWells Fargo
Success Rate
8/14 ratings generated profit
57%
Average Return
+4.46%
Copying Derek Archila's trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +4.46% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TCE1 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
6
14
14
20
15
Buy
9
11
14
11
8
Hold
1
2
2
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
27
30
35
27
In the current month, TCE1 has received 23 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TCE1 average Analyst price target in the past 3 months is 55.06.
Each month's total comprises the sum of three months' worth of ratings.

TCE1 Financial Forecast

TCE1 Earnings Forecast

Next quarter’s earnings estimate for TCE1 is -CHF0.85 with a range of -CHF0.89 to -CHF0.78. The previous quarter’s EPS was -CHF0.78. TCE1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TCE1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for TCE1 is -CHF0.85 with a range of -CHF0.89 to -CHF0.78. The previous quarter’s EPS was -CHF0.78. TCE1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TCE1 has Performed in-line its overall industry.

TCE1 Sales Forecast

Next quarter’s sales forecast for TCE1 is CHF601.65K with a range of CHF0.00 to CHF2.50M. The previous quarter’s sales results were CHF18.31K. TCE1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TCE1 has Performed in-line its overall industry.
Next quarter’s sales forecast for TCE1 is CHF601.65K with a range of CHF0.00 to CHF2.50M. The previous quarter’s sales results were CHF18.31K. TCE1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TCE1 has Performed in-line its overall industry.

TCE1 Stock Forecast FAQ

What is CH:TCE1’s average 12-month price target, according to analysts?
Based on analyst ratings, Celldex Therapeutics Inc’s 12-month average price target is 55.06.
    What is CH:TCE1’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:TCE1, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Celldex Therapeutics Inc a Buy, Sell or Hold?
        Celldex Therapeutics Inc has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Celldex Therapeutics Inc’s share price target?
          The average share price target for Celldex Therapeutics Inc is 55.06. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF83.22 ,and the lowest forecast is CHF23.30. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Celldex Therapeutics Inc?
            Celldex Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
              How can I buy shares of Celldex Therapeutics Inc?
              To buy shares of CH:TCE1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.